Englander-linked funds report 4.6% Quoin Pharmaceuticals (QNRX) stake
Rhea-AI Filing Summary
A group of investment entities associated with Israel A. Englander, including Integrated Core Strategies (US) LLC and Millennium Management LLC, reports beneficial ownership of 2,618,595 Quoin Pharmaceuticals ordinary shares, representing 4.6% of the class as of December 31, 2025.
The group reports only shared voting and dispositive power over these shares and no sole power. They state they have ceased to be beneficial owners of more than 5% of the outstanding ordinary shares and certify that the holdings are not for the purpose of influencing control of Quoin Pharmaceuticals.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake in Quoin Pharmaceuticals (QNRX) does the Englander group report?
The Englander-associated entities report owning 2,618,595 ordinary shares, or 4.6% of Quoin Pharmaceuticals’ outstanding class as of December 31, 2025. This stake is held with shared voting and dispositive power, and they report no sole authority over these shares.
Which entities are reporting beneficial ownership in Quoin Pharmaceuticals (QNRX)?
The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These related entities collectively report beneficial ownership of the same 2,618,595 ordinary shares of Quoin Pharmaceuticals’ ordinary shares.
Has the Englander group remained above the 5% ownership threshold in QNRX?
No. The reporting persons state they have ceased to be beneficial owners of more than 5% of Quoin’s outstanding ordinary shares. As of December 31, 2025, they report owning 4.6% of the class, below the 5% reporting threshold.
Does the Englander group seek to influence control of Quoin Pharmaceuticals (QNRX)?
The reporting persons certify that their Quoin holdings were not acquired and are not held to change or influence control of the issuer. They also state the securities are not held in connection with any transaction intended to affect control, other than limited nomination-related activities cited in the certification.
What security class and identifier does the Englander group disclosure for Quoin (QNRX) cover?
The disclosure covers Quoin Pharmaceuticals’ ordinary shares, no par value, linked to CUSIP 74907L409 assigned to its American Depositary Shares. Each American Depositary Share represents thirty-five ordinary shares, according to the comments accompanying the signatures.